Anaphylaxis during anaesthesia is most commonly an adverse drug reaction categorised as idiosyncratic and thus 'unpredictable'. Muscle relaxants, which are the commonest anaesthetic drugs to cause anaphylaxis, do so in approximately 1 in 5000 administrations in Australia and New Zealand. Given that these drugs are used in large numbers of patients with a relatively low incidence of anaphylaxis, and that skin testing for allergy to muscle relaxants has limited predictive value, preoperative screening for reactivity is unlikely to be practical. However, the arguments in favour of screening strengthen with drugs that are particularly allergenic. An example is chymopapain, used for chemonucleolysis. It was initially associated with anaphylaxis in as many as 1.5% of administrations, but the introduction of prior skin testing significantly reduced this incidence 1 .
Severe reactions to patent blue V dye (PBVD) are also common. The case series in this issue of Anaesthesia and Intensive Care is a further addition to the extensive literature on the dangers of this drug 2 . As long ago as 1981, when PBVD was used widely by radiologists, Kalimo et al reported that in 435 patients referred for lymphangiography, skinprick testing was positive in 2.8% 3 . This high rate of sensitisation in the population is presumed to be due to exposure to other chemically similar blue dyes used in industry and food production. Because the agent causing sensitisation to PBVD in the community is unknown, it is possible that there is regional variation in the prevalence of sensitisation. This has been demonstrated for muscle relaxant-induced anaphylaxis, the incidence of which varies as much as 30-fold between countries.
The recent Sentinel Node Versus Axillary Clearance trial provides some information about the incidence of PBVD allergy in Australia and New Zealand 4 . This multicentre study compared the extent of upper limb and shoulder girdle morbidity (e.g. lymphoedema) in women who had breast surgery with and without axillary clearance. Just over 1000 women received PBVD with only three allergic reactions, "none of them fatal". The phrase in quotation marks is a recognition that anaphylaxis is potentially life-threatening and raises questions about the medicolegal implications of PBVD administration, including the need for informed consent. Ten patients in the Sentinel Node Versus Axillary Clearance trial did not receive PBVD. The reasons for this were not reported, but in at least one instance it was because of a positive skin test (personal communication, D. Oliver). If a significant proportion of these ten patients were allergic to PBVD, then the rate of sensitisation in Australia and New Zealand may be in the order of one percent.
Because of the potential for anaphylaxis, some surgeons have abandoned the use of PBVD for identifying sentinel lymph nodes. Others cite the improved long-term outcomes due to more accurate sentinel node identification with the dye to justify the risk. However, this ignores the severe consequences of an adverse reaction, which apart from the potential life-threatening nature of the reaction itself, may lead to abandonment of the surgical procedure, with weeks of delay before completion.
At the present time it would seem inappropriate to recommend discontinuance of the use of PBVD, but can it be made safer? The answer is yes. The relatively small number of administrations and the high rate of anaphylaxis make screening eminently feasible. The PBVD product information leaflet (Rhone-Poulenc Rorer, Baulkham Hills, NSW) states, "It would seem prudent to test for hypersensitivity by injecting a very small volume of the solution and waiting a few moments to ascertain if there is a reaction." The Australian Adverse Drug Reactions Committee has supported this approach 5 . While this recommendation to screen for PBVD allergy has merit, the proposed method of testing has significant limitations. Use of a test dose (a Drug Provocation Test) is controversial, as there is no evidence that the incidence of anaphylaxis is reduced 6 . In a highly sensitised patient, a 'small' dose might cause anaphylaxis, and in a less sensitised individual, no response to the 'small' dose might invite a larger dose, which then may precipitate a reaction. Also, as demonstrated in the case series reported by Howard et al 2 , the response may be delayed by as long as 30 minutes, which would tax the patience of most surgeons! A more appropriate and validated screening tool is the skin test, either skin-prick or intradermal, which uses a much lower quantity of drug than a 'test dose'. Skin testing has high sensitivity and specificity. Of particular relevance to PBVD, when the prevalence of sensitisation in the population is high, Anaphylaxis to patent blue dye -misadventure or misdemeanour? the predictive value is also high. Some decades ago, the value of skin-prick testing was demonstrated in patients undergoing lymphangiography 3 . When PBVD use was restricted to patients who were skinprick test negative, only two of 423 patients (0.5%) exhibited symptoms, compared with six of 273 (2.2%) where skin-prick testing was not performed. Two patients who had reactions and who were presumably sensitised to blue dye were not identified as such by skin-prick. A recent review concluded that, in the investigation of PBVD-triggered anaphylaxis, the sensitivity of intradermal testing was 100%, compared with 80% for skin-prick testing 7 ; thus, intradermal testing should improve the predictive value of screening. However, there has been no prospective study that has confirmed this for PBVD.
A recent article in the journal Allergy described six cases of PBVD-related allergic phenomena, some of which were life-threatening 8 . The authors concluded that there was a good argument for prospective skin testing, but that it would be "impractical". We disagree. Skin testing is simple to perform and interpret. Preparation for breast cancer surgery involves other procedures such as a chest X-ray or hookwire insertion that are manifestly more complex or time-consuming.
Most breast surgeons in Western Australia who use PBVD on a regular basis have direct experience of allergic reactions to this drug. Many have introduced some form of preoperative screening. In 2004, Ingram et al reported a case of anaphylaxis caused by PBVD in the Australian and New Zealand Journal of Surgery 9 . They described their protocol for its use, which in short recommended: informed patient consent; only using PBVD if lymphoscintography does not satisfactorily identify a sentinel lymph node; a skin-prick test if PBVD is to be used; and informing the anaesthetist that the drug is to be administered, along with ensuring that he or she is aware of the potential adverse consequences.
These recommendations are commendable, but appear not to have been widely adopted. The principal author of this editorial (PP) has recently investigated a case of PBVD anaphylaxis when there was no informed consent, and the anaesthetist was not advised that PBVD was to be used. After the severe reaction the patient was transferred to the intensive care unit at our institution for ongoing care. The referral letter made no mention that PBVD had been administered, which led to delays in determining the cause of the reaction and to rescheduling of the surgical procedure.
There is no widely accepted Australian guideline for PBVD allergy screening. Many conscientious surgeons have devised their own protocols. Unfortunately, some of these have dubious merit and a more standardised approach is required. The second phase of the Sentinel Node Versus Axillary Clearance trial would be an ideal opportunity to introduce a protocol for the screening of breast cancer patients for PBVD allergy. This would require consultation between surgeons, anaesthetists and immunologists. Detractors of this proposal may argue that false positive skin tests could unnecessarily preclude patients from receiving PBVD, but the use of a standardised intradermal screening protocol would make this extremely uncommon and, in this setting, there are other means of finding sentinel nodes.
In the absence of screening, an anaphylactic reaction caused by PBVD can no longer be considered wholly a misadventure. There are ways of identifying patients allergic to this drug preoperatively as well as alternative agents and surgical techniques that can be used in those with a positive skin test. At what stage will failure to screen for allergy to PBVD before its administration become a misdemeanour?
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